ロード中...
The impact of discontinuation of sacubitril–valsartan and shifting to angiotensin-converting enzyme inhibitor or angiotensin receptor blocker in patients with heart failure with reduced ejection fraction
OBJECTIVE: Many trials confirmed the role of sacubitril–valsartan in the treatment of patients with heart failure with reduced ejection fraction (HFrEF). However, there is no sufficient data to register the effect of compulsory discontinuation of sacubitril–valsartan, either because of financial sho...
保存先:
| 出版年: | Anatol J Cardiol |
|---|---|
| 主要な著者: | , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Turkish Society of Cardiology
2021
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8114728/ https://ncbi.nlm.nih.gov/pubmed/33690130 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.14744/AnatolJCardiol.2020.39267 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|